Proposal for distribution and separate listing of Infant Bacterial Therapeutics from BioGaia
February 19, 2016

The board of directors of parent company BioGaia AB (publ) has resolved to propose to an Extraordinary General Meeting in BioGaia on 18 March 2016 to distribute the shares in the subsidiary Infant Bacterial Therapeutics AB (publ) (“IBT”) to the shareholders of BioGaia. In connection with the execution of the dividend, IBT will apply for a listing of its series B shares on Nasdaq First North. To finance IBT’s first clinical trial, the company has, as previously communicated, a capital need of approximately SEK 100 million, which is planned to be raised through a rights issue with preferential rights for IBT’s shareholders during the second quarter 2016.


Read more the official BioGaia press release here